Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# $otsky

Breaking: $OTSKY mentioned in multiple analyst reports from TD Cowen, Raymond James, H.C. Wainwright, and Cantor, with price targets ranging from $XX to $XXX. These reports highlight the drug sibeprenlimab's approval and market potential in IgAN.

### About $otsky
$otsky is a digital asset and blockchain project.  

### Engagements: X (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/interactions.tsv)  
Current Value: X  
Daily Average: XXX  
X Week: XXXXX -XX%  
X Month: XXXXXX +479%  
X Months: XXXXXX -XX%  
X Year: XXXXXXX +585%  
1-Year High: XXXXXX on 2025-02-03  
1-Year Low: X on 2024-12-26  

Engagements by network (24h):
X: X

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: X  
X Week: XX -XXXX%  
X Month: XX -XX%  
X Months: XXX +103%  
X Year: XXX +184%  
1-Year High: XX on 2025-10-26  
1-Year Low: X on 2024-12-11  

Mentions by network (24h):
X: X

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $otsky in the last XX hours which is no change from in the previous XX hours
Daily Average: X  
X Week: X -XX%  
X Month: X -XX%  
X Months: XX +21%  
X Year: XX +100%  
1-Year High: XX on 2025-06-25  
1-Year Low: X on 2024-12-11  

The most influential creators that mention $otsky in the last XX hours

| Creator                                    | Rank | Followers | Posts | Engagements |
| -------                                    | ---- | --------- | ----- | ----------- |
| [@Quantumup1](/creator/twitter/Quantumup1) | X    | XXXXX     | X     | XX          |

[View More](/list/creators/$otsky/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$otsky/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$otsky/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% no change  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% +10%  
1-Year High: XXX% on 2025-01-15  
1-Year Low: XX% on 2025-09-12  

Most Supportive Themes:
- Creator Activity Surge: (33%) The number of active creators mentioning $otsky has seen a significant increase, indicating growing interest and participation from content creators.
- Engagement Growth: (33%) While current engagements are low, the 1-year growth of XXX% suggests a strong historical engagement trend for $otsky.
- Mention Volume Increase: (33%) Mentions of $otsky have surged by 1080% month-over-month, pointing to a rapid increase in public discourse and awareness.
  
Most Critical Themes:
  

### Top $otsky Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"H.C. Wainwright reiterated $VERA Buy-$90 and saidOn November XX the FDA granted accelerated approval (AA) to sibeprenlimab marketed as Voyxact by Otsuka ( $OTSKY; not rated) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). $TVTX NVS JBIO VRTX ABBV ALNY IONS H.C. Wainwright addedThis approval was highly anticipated given that sibeprenlimab achieved the primary endpoint of reduction in urine protein creatinine ratio (UPCR) in the ongoing Phase X VISIONARY study. One highlight from sibeprenlimab's AA label is the absence of a UPCR cutoff to define IgAN patients "at"  
[X Link](https://x.com/Quantumup1/status/1994378715053068735) [@Quantumup1](/creator/x/Quantumup1) 2025-11-28T12:11Z 3919 followers, 5209 engagements


"Cantor reit'd $VERA OW-$100/saidWe continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30) given the competitive profile in lgAN a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO ALNY ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a $10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria XXX g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized"  
[X Link](https://x.com/Quantumup1/status/1993656292674576894) [@Quantumup1](/creator/x/Quantumup1) 2025-11-26T12:21Z 3919 followers, 10.6K engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$otsky

Breaking: $OTSKY mentioned in multiple analyst reports from TD Cowen, Raymond James, H.C. Wainwright, and Cantor, with price targets ranging from $XX to $XXX. These reports highlight the drug sibeprenlimab's approval and market potential in IgAN.

About $otsky

$otsky is a digital asset and blockchain project.

Engagements: X (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XXX
X Week: XXXXX -XX%
X Month: XXXXXX +479%
X Months: XXXXXX -XX%
X Year: XXXXXXX +585%
1-Year High: XXXXXX on 2025-02-03
1-Year Low: X on 2024-12-26

Engagements by network (24h): X: X

Mentions: X (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX -XXXX%
X Month: XX -XX%
X Months: XXX +103%
X Year: XXX +184%
1-Year High: XX on 2025-10-26
1-Year Low: X on 2024-12-11

Mentions by network (24h): X: X

Creators: X (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $otsky in the last XX hours which is no change from in the previous XX hours Daily Average: X
X Week: X -XX%
X Month: X -XX%
X Months: XX +21%
X Year: XX +100%
1-Year High: XX on 2025-06-25
1-Year Low: X on 2024-12-11

The most influential creators that mention $otsky in the last XX hours

Creator Rank Followers Posts Engagements
@Quantumup1 X XXXXX X XX

View More

Sentiment: XXX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XXX% no change
X Month: XXX% no change
X Months: XXX% no change
X Year: XXX% +10%
1-Year High: XXX% on 2025-01-15
1-Year Low: XX% on 2025-09-12

Most Supportive Themes:

  • Creator Activity Surge: (33%) The number of active creators mentioning $otsky has seen a significant increase, indicating growing interest and participation from content creators.
  • Engagement Growth: (33%) While current engagements are low, the 1-year growth of XXX% suggests a strong historical engagement trend for $otsky.
  • Mention Volume Increase: (33%) Mentions of $otsky have surged by 1080% month-over-month, pointing to a rapid increase in public discourse and awareness.

Most Critical Themes:

Top $otsky Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"H.C. Wainwright reiterated $VERA Buy-$90 and saidOn November XX the FDA granted accelerated approval (AA) to sibeprenlimab marketed as Voyxact by Otsuka ( $OTSKY; not rated) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). $TVTX NVS JBIO VRTX ABBV ALNY IONS H.C. Wainwright addedThis approval was highly anticipated given that sibeprenlimab achieved the primary endpoint of reduction in urine protein creatinine ratio (UPCR) in the ongoing Phase X VISIONARY study. One highlight from sibeprenlimab's AA label is the absence of a UPCR cutoff to define IgAN patients "at"
X Link @Quantumup1 2025-11-28T12:11Z 3919 followers, 5209 engagements

"Cantor reit'd $VERA OW-$100/saidWe continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30) given the competitive profile in lgAN a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO ALNY ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a $10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria XXX g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized"
X Link @Quantumup1 2025-11-26T12:21Z 3919 followers, 10.6K engagements

$otsky
/topic/$otsky